Tuberculosis-HIV co-infection in an era of complex, rapid new drug development
| dc.contributor.author | Venter, Francois | |
| dc.contributor.author | Niyongabo, Bienvenu | |
| dc.date.accessioned | 2024-02-01T09:06:40Z | |
| dc.date.issued | 2023-10 | |
| dc.description.abstract | No abstract available. | en_US |
| dc.description.department | School of Health Systems and Public Health (SHSPH) | en_US |
| dc.description.embargo | 2024-10-01 | |
| dc.description.librarian | hj2024 | en_US |
| dc.description.sdg | None | en_US |
| dc.description.sponsorship | The Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, Unitaid, Foundation for Innovative New Diagnostics (FIND), and the Children’s Investment Fund Foundation (CIFF), has previously received funding from USAID and receives drug donations from ViiV Healthcare, Merck, J&J and Gilead Sciences for investigator-led clinical studies. | en_US |
| dc.description.uri | http://journals.lww.com/aidsonline | en_US |
| dc.identifier.citation | Venter, F. & Niyongabo, B. 2023, 'Tuberculosis-HIV co-infection in an era of complex, rapid new drug development', AIDS, vol. 37, no. 12, pp. 1897-1898, doi : 10.1097/QAD.0000000000003584. | en_US |
| dc.identifier.issn | 0269-9370 (print) | |
| dc.identifier.issn | 1473-5571 (online) | |
| dc.identifier.other | 10.1097/QAD.0000000000003584 | |
| dc.identifier.uri | http://hdl.handle.net/2263/94218 | |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott, Williams & Wilkins | en_US |
| dc.rights | © 2023 Wolters Kluwer Health, Inc. All rights reserved. This is a non-final version of an article published in final form in AIDS, vol. , no. , pp. , 2023, doi : [12 months embargo] | en_US |
| dc.subject | Tuberculosis–HIV co-infection | en_US |
| dc.subject | Tuberculosis (TB) | en_US |
| dc.subject | Human immunodeficiency virus (HIV) | en_US |
| dc.subject | Editorial comment | en_US |
| dc.subject | Drug development | en_US |
| dc.title | Tuberculosis-HIV co-infection in an era of complex, rapid new drug development | en_US |
| dc.type | Postprint Article | en_US |